A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

29 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis

NCT01858259

Systemic Sclerosis Interstitial Lung Diseases

UNKNOWN

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

NCT00883129

Scleroderma Interstitial Lung Disease

COMPLETED PHASE2

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933

Scleroderma, Systemic

COMPLETED PHASE3

Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis

NCT07015060

Scleroderma (Limited and Diffuse)

NOT_YET_RECRUITING NA

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

NCT05726630

Systemic Scleroderma

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma. The first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin discoloration and sometimes patients experience high blood pressure in their arteries. The second type is called diffuse cutaneous scleroderma and it is much more aggressive, affecting a larger area of skin causing organ damage. This study will determine if the disease is associated with an elevated expression of LOXL2 levels in tissue samples from patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Limited Scleroderma Diffuse Scleroderma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Limited Scleroderma

No interventions assigned to this group

Diffuse Scleroderma

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years of age
* Documented diagnosis of scleroderma
* Willing and able to provide written informed consent

Exclusion Criteria

* Use of experimental therapies within 28 days prior to Screening.
* Aspirin use \> 81 mg daily within 1 week prior to Screening.
* Any lab abnormality or concurrent medical condition that, in the opinion of the investigator would make the patient ineligible for the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No